Recently, Mabwell and PKUCare Luzhong Hospital held a signing and unveiling ceremony for drug clinical research cooperation, formally establishing a strategic alliance. Dr. Guo Yinhan, CDO of Mabwell, and Gu Guoming, Party secretary and president of PKUCare Luzhong Hospital, signed a strategic cooperation agreement on behalf of their corresponding parties, and unveiled the "Drug Clinical Research Center". More than 30 guests and experts from Mabwell, GoBroad Healthcare Group, and PKUCare Luzhong Hospital witnessed the signing ceremony.

Wang Jidong, executive vice president of PKUCare Luzhong Hospital, presided over the ceremony.

Gu Guoming, Party secretary and president of PKUCare Luzhong Hospital, delivered welcome speech, introduced the development history of drug clinical trials in Luzhong Hospital, and expressed his expectation for cooperation with Mabwell.

Zheng Xiaoyu, chief operating officer of the Clinical Research Center of GoBroad Healthcare Group, presented the background on GoBroad, and expressed the hope that the cooperation of hospitals and companies could lead to sharing and growth to realize resource integration and innovative development.

Dr. Guo Yinhan, CDO of Mabwell, said that Mabwell has long-reaching ties to Luzhong Hospital, and expressed the hope for a bright future of clinical research and development of innovative drugs through joint efforts.

In addition to the Phase III clinical study 9MW0813, the two parties also signed cooperatively on several other clinical trial projects during the signing ceremony, which will be conducted by the Phase I Clinical Trial Department and the Ophthalmology Department, PKUCare Luzhong Hospital, respectively. The two parties will establish a close strategic partnership based on the principle of "mutual complementarity for win win", commit to the clinical research of new drugs, and drive forward pharmaceutical innovation in China.

In recent years, drug clinical research in China has been developing rapidly. Mabwell will establish a close strategic partnership with PKUCare Luzhong Hospital, put to use a better clinical trial management and implementation process, to ensure the quality of clinical trials, improve the efficiency of clinical trial implementation, build the core base of clinical trials and promote the development of new drugs in China, and facilitate the development of China's big health industry.

About PKUCare Luzhong Hospital

PKUCare Luzhong Hospital is of class-A Tier general hospital under PKU HealthCare Industry Group, integrating healthcare, research, teaching, and first aid. In May 2017, it obtained the qualification certificate from the National Medical Products Administration. The hospital has 9 clinical specialties, including Burns, Gastroenterology, Cardiovascular Medicine, Respiratory Medicine, Endocrinology, Tumor, Blood, Neurology, and Ophthalmology, and a Phase 1 Clinical Trial Department, which was configured and constructed under international standards. Dr. Hou Jie, an expert of the Center for Drug Evaluation and the Center for Food and Drug Inspection of NMPA, was appointed as the director of the Phase 1 Clinical Trial Department, which has 100 beds and more than 40 full-time researchers. The hospital has undertaken over 100 clinical trial projects and ranked at the province's forefront.